Suppr超能文献

人 T 淋巴细胞中 CXCR3 变体的表达和激动剂反应性。

Expression and agonist responsiveness of CXCR3 variants in human T lymphocytes.

机构信息

Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath, UK.

出版信息

Immunology. 2011 Apr;132(4):503-15. doi: 10.1111/j.1365-2567.2010.03384.x. Epub 2011 Jan 24.

Abstract

The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 are involved in variety of inflammatory disorders including multiple sclerosis, rheumatoid arthritis, psoriasis and sarcoidosis. Two alternatively spliced variants of the human CXCR3-A receptor have been described, termed CXCR3-B and CXCR3-alt. Human CXCR3-B binds CXCL9, CXCL10, CXCL11 as well as an additional ligand CXCL4. In contrast, CXCR3-alt only binds CXCL11. We report that CXCL4 induces intracellular calcium mobilization as well as Akt and p44/p42 extracellular signal-regulated kinase phosphorylation, in activated human T lymphocytes. These responses have similar concentration dependence and time-courses to those induced by established CXCR3 agonists. Moreover, phosphorylation of Akt and p44/p42 is inhibited by pertussis toxin, suggesting coupling to Gα(i) protein. Surprisingly, and in contrast with the other CXCR3 agonists, stimulation of T lymphocytes with CXCL4 failed to elicit migratory responses and did not lead to loss of surface CXCR3 expression. Taken together, our findings show that, although CXCL4 is coupled to downstream biochemical machinery, its role in T cells is probably distinct from that of CXCR3-A agonists.

摘要

趋化因子受体 CXCR3 及其配体 CXCL9、CXCL10 和 CXCL11 参与多种炎症性疾病,包括多发性硬化症、类风湿性关节炎、银屑病和结节病。人类 CXCR3-A 受体的两种选择性剪接变体已被描述,分别称为 CXCR3-B 和 CXCR3-alt。人 CXCR3-B 结合 CXCL9、CXCL10、CXCL11 以及另外一种配体 CXCL4。相比之下,CXCR3-alt 仅结合 CXCL11。我们报告说,CXCL4 可诱导活化的人 T 淋巴细胞内钙动员以及 Akt 和 p44/p42 细胞外信号调节激酶磷酸化。这些反应与已建立的 CXCR3 激动剂诱导的反应具有相似的浓度依赖性和时间进程。此外,Akt 和 p44/p42 的磷酸化被百日咳毒素抑制,表明与 Gα(i)蛋白偶联。令人惊讶的是,与其他 CXCR3 激动剂相反,用 CXCL4 刺激 T 淋巴细胞不能引发迁移反应,也不会导致表面 CXCR3 表达的丧失。总之,我们的研究结果表明,尽管 CXCL4 与下游生化机制偶联,但它在 T 细胞中的作用可能与 CXCR3-A 激动剂不同。

相似文献

1
Expression and agonist responsiveness of CXCR3 variants in human T lymphocytes.
Immunology. 2011 Apr;132(4):503-15. doi: 10.1111/j.1365-2567.2010.03384.x. Epub 2011 Jan 24.
2
Label-free impedance responses of endogenous and synthetic chemokine receptor CXCR3 agonists correlate with Gi-protein pathway activation.
Biochem Biophys Res Commun. 2012 Mar 9;419(2):412-8. doi: 10.1016/j.bbrc.2012.02.036. Epub 2012 Feb 13.
3
CXC Chemokine Receptor 3 Alternative Splice Variants Selectively Activate Different Signaling Pathways.
Mol Pharmacol. 2016 Oct;90(4):483-95. doi: 10.1124/mol.116.105502. Epub 2016 Aug 10.
4
Interleukin-27 and IFNγ regulate the expression of CXCL9, CXCL10, and CXCL11 in hepatitis.
J Mol Med (Berl). 2015 Dec;93(12):1355-67. doi: 10.1007/s00109-015-1319-6. Epub 2015 Jul 23.
5
Evidence for PI3K-dependent CXCR3 agonist-induced degranulation of human cord blood-derived mast cells.
Mol Immunol. 2010 Aug;47(14):2367-77. doi: 10.1016/j.molimm.2010.05.005. Epub 2010 Jun 2.
7
Analysis of CXCR3 and atypical variant expression and signalling in human T lymphocytes.
Methods Mol Biol. 2010;616:125-47. doi: 10.1007/978-1-60761-461-6_9.
9
CXCL4-induced migration of activated T lymphocytes is mediated by the chemokine receptor CXCR3.
J Leukoc Biol. 2008 Apr;83(4):875-82. doi: 10.1189/jlb.1006645. Epub 2008 Jan 3.

引用本文的文献

1
GPATCH3, a splicing regulator that facilitates tumor immune evasion via the modulation of ATPase activity of DHX15.
Front Immunol. 2025 Aug 11;16:1612461. doi: 10.3389/fimmu.2025.1612461. eCollection 2025.
2
Non-immune targeting of CXCR3 compromises mitochondrial function and suppresses tumor growth in glioblastoma.
Cell Death Discov. 2025 Apr 4;11(1):143. doi: 10.1038/s41420-025-02449-1.
4
Get Spliced: Uniting Alternative Splicing and Arthritis.
Int J Mol Sci. 2024 Jul 25;25(15):8123. doi: 10.3390/ijms25158123.
5
Atypical chemokine receptors in the immune system.
Nat Rev Immunol. 2024 Oct;24(10):753-769. doi: 10.1038/s41577-024-01025-5. Epub 2024 May 7.
8
Platelet factors attenuate inflammation and rescue cognition in ageing.
Nature. 2023 Aug;620(7976):1071-1079. doi: 10.1038/s41586-023-06436-3. Epub 2023 Aug 16.
9
Targeting CXCL9/10/11-CXCR3 axis: an important component of tumor-promoting and antitumor immunity.
Clin Transl Oncol. 2023 Aug;25(8):2306-2320. doi: 10.1007/s12094-023-03126-4. Epub 2023 Apr 19.

本文引用的文献

1
Evidence for PI-3K-dependent migration of Th17-polarized cells in response to CCR2 and CCR6 agonists.
J Leukoc Biol. 2008 Oct;84(4):1202-12. doi: 10.1189/jlb.0408234. Epub 2008 Jun 27.
2
CXCL4-induced migration of activated T lymphocytes is mediated by the chemokine receptor CXCR3.
J Leukoc Biol. 2008 Apr;83(4):875-82. doi: 10.1189/jlb.1006645. Epub 2008 Jan 3.
5
Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors.
Trends Pharmacol Sci. 2007 Aug;28(8):407-15. doi: 10.1016/j.tips.2007.06.009. Epub 2007 Jul 13.
6
Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates.
Trends Pharmacol Sci. 2007 Aug;28(8):374-81. doi: 10.1016/j.tips.2007.06.011. Epub 2007 Jul 13.
7
Chemokines and their receptors as potential targets for the treatment of asthma.
Br J Pharmacol. 2007 Jul;151(6):725-36. doi: 10.1038/sj.bjp.0707263. Epub 2007 Apr 30.
8
Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3.
Bioorg Med Chem Lett. 2007 Jun 15;17(12):3339-43. doi: 10.1016/j.bmcl.2007.03.106. Epub 2007 Apr 6.
10
Temporal variation in CB2R levels following T lymphocyte activation: evidence that cannabinoids modulate CXCL12-induced chemotaxis.
Int Immunopharmacol. 2007 Mar;7(3):360-71. doi: 10.1016/j.intimp.2006.11.008. Epub 2006 Dec 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验